Condition: Hematuria · Cystoscopy · Urothelial Carcinoma Bladder · Sponsor: Nucleix Ltd.
The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed. Participants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.
This description comes directly from the study's public registry record.
Vered Yayon · +972-8-9161616 · vered.y@nucleix.com
Admin. · info@nucleix.com
Always discuss trial participation with your own doctor first.
| NHS Fife | Dunfermline, Fife, United Kingdom | Recruiting |
| Addenbrooke's Hospital | Cambridge, United Kingdom | Recruiting |
| NHS Lothian | Edinburgh, United Kingdom | Recruiting |
| Guy's and St Thomas | London, United Kingdom | Recruiting |
| Frimley | Surrey Quays, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06818136